PARSIPPANY, NJ--(Marketwired - May 9, 2013) - The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for RECOTHROM®, Thrombin ...

ZymoGenetics said Monday it regained most of the marketing rights for its only marketed product, Recothrom, from partner Bayer Schering Pharma. The Seattle-based biotechnology company said that ...

Additional Recothrom vial size approved The FDA has approved ZymoGenetics' Recothrom (recombinant topical thrombin) for use as an aid to hemostasis when oozing blood and minor bleeding from ...

Additional Recothrom vial size approved The FDA has approved a 20000 IU vial size of Recothrom (recombinant topical thrombin, from ZymoGenetics) in addition to the 5000 IU vial already available. The ...

In a letter released Wednesday, the Food and Drug Administration rebuked Seattle-based ZymoGenetics for suggesting in a news release that its first product, Recothrom, is safer than a rival treatment ...

Baxter International in Deerfield, agreed to acquire two hemostat and sealant products from British-based Mallinckrodt Pharmaceuticals: Recothrom, the first and only standalone recombinant thrombin, ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global medical products company, is committed to advancing surgical innovation and today announced it has completed its ...

RECOTHROM Thrombin topical (Recombinant) is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of ...

The Food and Drug Administration says ZymoGenetics omitted important facts when announcing the launch of its first commercial product, Recothrom, and it has asked the company to revise the news ...

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Baxter International and Mallinckkrodt most recent news is on our ...

ZymoGenetics Inc., developer and manufacturer of therapeutic proteins, was told by the Food and Drugs Administration that its promotion of the treatment Recothrom had false and misleading material ...

Baxter International Inc.BAX has completed the acquisition of two hemostat and sealant products from Mallinckrodt plc to widen its existing surgical portfolio of hemostats and sealants, especially for ...